Ashraf Nashed, MD
Cardiovascular Disease · Thousand Oaks, CANPI 1144290081
Payments from drug & device makers
Across 562 payments — averaging $40.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$4K
- Abbott$3K
- Biotronik Inc.$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Novartis$1K
- plus $9K from 45 others
What the payments were for
- Travel & lodging$4,03518%
- Food & beverage$16,68374%
- Education$1,9699%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MRI Equip Undiv$1,672
- (6554) Peripheral Vascular Undivided$809
- Barostim Neo System$542
- VERQUVO$487
- FARXIGA$485
- Quadra Assura CRT Defibrillator$470
- QUADRA ASSURA$449
- (6575) Coronary Undivided$426
- Diamondback Coronary$418
- (9520) IGT Devices Undivided$360
- Repatha$357
- Confirm Rx$255
- Vascepa$248
- BRILINTA$237
- JARDIANCE$229
- US Und$214
- TactiCath Quartz CFA Catheter$165
- Fortify Assura$150
- XACT$149
- UPTRAVI$142
How this compares
$22,687 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 376 | $359,652 |
| MounjaroTirzepatide | 271 | $289,493 |
| JardianceEmpagliflozin | 415 | $267,093 |
| EliquisApixaban | 416 | $233,580 |
| Diclofenac Sodium | 119 | $204,869 |
| XareltoRivaroxaban | 266 | $156,395 |
| LinzessLinaclotide | 196 | $105,166 |
| EntrestoSacubitril/Valsartan | 114 | $94,141 |
| JanuviaSitagliptin Phosphate | 162 | $92,379 |
| ForteoTeriparatide | 20 | $88,389 |
| TrulicityDulaglutide | 87 | $81,650 |
| MultaqDronedarone Hcl | 97 | $79,919 |
| ProliaDenosumab | 42 | $74,119 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $64,834 |
| VascepaIcosapent Ethyl | 152 | $62,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $586 | $459,532378 claims |
| Novo NordiskOzempic | $80 | $359,652376 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $1,244 | $276,008433 claims |
| PfizerEliquis, Lyrica | $203 | $240,462428 claims |
| Johnson & JohnsonXarelto | $411 | $156,395266 claims |
| AbbVieLinzess, Creon | $30 | $129,981236 claims |
| MerckJanuvia, Verquvo | $739 | $105,157180 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $129 | $96,728172 claims |
| NovartisEntresto | $1,214 | $94,141114 claims |
| Sanofi-aventis U.S. LLCMultaq | $35 | $79,91997 claims |
| AmgenProlia | $564 | $74,11942 claims |
| AstraZenecaBrilinta, Farxiga | $1,975 | $52,12790 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Thousand Oaks
- Irving LohThousand Oaks$1.1M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.